This molecular classification, which divides breast cancer into three subtypes—mTNBC, HR+/HER2−, and HR+/HER2+—allows for the identification of subtypes with distinct therapeutic and prognostic profiles [2]. This evidence concerns the gene ERBB2 and breast carcinoma.